These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15374884)

  • 1. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
    Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E
    Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity.
    Zeng Y; Feng H; Graner MW; Katsanis E
    Blood; 2003 Jun; 101(11):4485-91. PubMed ID: 12576309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
    He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
    Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
    Kislin KL; Marron MT; Li G; Graner MW; Katsanis E
    FASEB J; 2007 Jul; 21(9):2173-84. PubMed ID: 17327358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.
    Zeng Y; Graner MW; Feng H; Li G; Katsanis E
    Int J Cancer; 2004 Jun; 110(2):251-9. PubMed ID: 15069690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity.
    Chen X; Zeng Y; Li G; Larmonier N; Graner MW; Katsanis E
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):275-83. PubMed ID: 16503496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells.
    Feng H; Zeng Y; Graner MW; Katsanis E
    Blood; 2002 Dec; 100(12):4108-15. PubMed ID: 12393401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro].
    Wang WW; Huang RW; Hu Y; Li XD; Wang DN; He Y; Liu JJ
    Ai Zheng; 2009 Jun; 28(6):602-6. PubMed ID: 19635197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
    Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
    Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.
    Janikashvili N; LaCasse CJ; Larmonier C; Trad M; Herrell A; Bustamante S; Bonnotte B; Har-Noy M; Larmonier N; Katsanis E
    Blood; 2011 Feb; 117(5):1555-64. PubMed ID: 21123824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL-specific CD4
    Ueda N; Zhang R; Tatsumi M; Liu TY; Kitayama S; Yasui Y; Sugai S; Iwama T; Senju S; Okada S; Nakatsura T; Kuzushima K; Kiyoi H; Naoe T; Kaneko S; Uemura Y
    Cell Mol Immunol; 2018 Jan; 15(1):15-26. PubMed ID: 27181332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
    Chen W; Qin H; Reese VA; Cheever MA
    J Immunother; 1998 Jul; 21(4):257-68. PubMed ID: 9672847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
    Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
    Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccination against bcr-abl-positive cells in mice.
    Lucansky V; Sobotkova E; Tachezy R; Duskova M; Vonka V
    Int J Oncol; 2009 Oct; 35(4):941-51. PubMed ID: 19724931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with leukemia-loaded dendritic cells eradicates residual disease and prevent relapse.
    Deeb D; Gao X; Jiang H; Divine G; Dulchavsky SA; Gautam SC
    J Exp Ther Oncol; 2006; 5(3):183-93. PubMed ID: 16528969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
    Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H
    J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O
    Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.
    Makita M; Azuma T; Hamaguchi H; Niiya H; Kojima K; Fujita S; Tanimoto M; Harada M; Yasukawa M
    Leukemia; 2002 Dec; 16(12):2400-7. PubMed ID: 12454745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaperone-rich cell lysates, immune activation and tumor vaccination.
    Zeng Y; Graner MW; Katsanis E
    Cancer Immunol Immunother; 2006 Mar; 55(3):329-38. PubMed ID: 15887013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.